Bal Pharma Limited

Bal Pharma Limited (BALPHARMA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

balpharma.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-09-03

Stock price
₹87.71
Market cap
139 Cr
Stock P/E
19.1
P/B
1.70
Dividend yield
0.0%

Sign in for full ratios and TTM. Learn about these metrics →

Share price

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales93 Cr82 Cr95 Cr74 Cr74 Cr73 Cr82 Cr66 Cr74 Cr88 Cr84 Cr89 Cr
Operating expenses (approx.)85 Cr74 Cr85 Cr68 Cr66 Cr65 Cr74 Cr60 Cr68 Cr78 Cr74 Cr81 Cr
EBITDA8 Cr8 Cr10 Cr6 Cr8 Cr8 Cr8 Cr6 Cr6 Cr10 Cr11 Cr8 Cr
OPM %8.3%9.5%10.1%8.7%10.4%10.6%9.3%9.2%7.7%10.9%12.6%9.0%
Other income0.14 Cr0.10 Cr2 Cr0.82 Cr-0.20 Cr0.51 Cr1 Cr0.72 Cr1 Cr0.33 Cr-0.24 Cr0.44 Cr
Interest4 Cr4 Cr4 Cr4 Cr4 Cr5 Cr4 Cr4 Cr4 Cr5 Cr4 Cr4 Cr
Depreciation2 Cr3 Cr2 Cr2 Cr2 Cr3 Cr2 Cr3 Cr2 Cr3 Cr3 Cr3 Cr
Profit before tax2 Cr1 Cr6 Cr0.62 Cr1 Cr0.57 Cr3 Cr0.21 Cr0.72 Cr2 Cr3 Cr1 Cr
Tax %39.4%32.9%3.8%58.0%23.5%8.5%-110.8%0.0%0.0%0.0%-12.0%0.0%
Net profit0.97 Cr0.85 Cr6 Cr0.26 Cr1 Cr0.52 Cr5 Cr0.21 Cr0.72 Cr2 Cr4 Cr1 Cr
EPS (₹)₹0.62₹0.54₹3.73₹0.16₹0.65₹0.33₹3.40₹0.13₹0.45₹1.12₹2.26₹0.71

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales171 Cr251 Cr281 Cr304 Cr339 Cr303 Cr312 CrSign in for TTM
Operating expenses (approx.)166 Cr226 Cr258 Cr279 Cr308 Cr274 Cr280 CrSign in for TTM
EBITDA5 Cr24 Cr23 Cr25 Cr32 Cr30 Cr32 CrSign in for TTM
OPM %2.8%9.8%8.3%8.3%9.3%9.8%10.2%Sign in for TTM
Other income2 Cr1 Cr5 Cr0.94 Cr3 Cr2 Cr2 CrSign in for TTM
Interest12 Cr12 Cr10 Cr12 Cr15 Cr17 Cr17 CrSign in for TTM
Depreciation8 Cr10 Cr9 Cr9 Cr10 Cr10 Cr11 CrSign in for TTM
Profit before tax-14 Cr4 Cr9 Cr5 Cr9 Cr5 Cr6 CrSign in for TTM
Tax %4.7%-14.9%37.9%44.8%17.7%-41.1%-6.5%Sign in for TTM
Net profit-13 Cr5 Cr6 Cr3 Cr7 Cr7 Cr6 CrSign in for TTM
EPS (₹)₹-8.62₹3.34₹3.79₹1.67₹4.94₹4.56₹3.95Sign in for TTM
Dividend payout %——0.0%0.0%0.0%0.0%0.3%Sign in for TTM
Sign in for TTM

Trailing twelve months totals and margin rows

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital14 Cr15 Cr15 Cr16 Cr16 Cr16 Cr16 Cr
Reserves38 Cr39 Cr44 Cr48 Cr53 Cr61 Cr66 Cr
Borrowings113 Cr105 Cr104 Cr131 Cr140 Cr150 Cr160 Cr
Other liabilities80 Cr82 Cr100 Cr118 Cr111 Cr108 Cr134 Cr
Total liabilities238 Cr240 Cr262 Cr313 Cr320 Cr336 Cr376 Cr
Fixed assets (net)60 Cr58 Cr56 Cr62 Cr62 Cr71 Cr77 Cr
CWIP3 Cr0 Cr2 Cr0 Cr0.47 Cr3 Cr7 Cr
Investments0 Cr4 Cr0 Cr0 Cr7 Cr2 Cr2 Cr
Loans & advances2 Cr2 Cr2 Cr0.96 Cr1 Cr1 Cr0 Cr
Inventories68 Cr60 Cr74 Cr98 Cr88 Cr103 Cr116 Cr
Trade receivables50 Cr67 Cr75 Cr94 Cr100 Cr92 Cr94 Cr
Cash & bank0.86 Cr1 Cr1 Cr1 Cr4 Cr2 Cr2 Cr
Other assets54 Cr48 Cr52 Cr57 Cr59 Cr61 Cr77 Cr
Total assets238 Cr240 Cr262 Cr313 Cr320 Cr336 Cr376 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity——32 Cr23 Cr329 Cr21 Cr8 Cr
Cash from investing——11 Cr18 Cr0 Cr-18 Cr-10 Cr
Cash from financing——1 Cr0 Cr35 Cr0.29 Cr-27 Cr
Net cash flow——44 Cr41 Cr364 Cr3 Cr-29 Cr
Free cash flow (OCF − Capex)——32 Cr23 Cr329 Cr21 Cr8 Cr

Ratios

Ratios as reported or derived per annual period.

MetricMar 2020BSE balance sheet (this exchange's own filing had none for this period)Mar 2021BSE balance sheet (this exchange's own filing had none for this period)Mar 2022BSE balance sheet (this exchange's own filing had none for this period)Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %-0.7%10.2%33.4%8.7%11.6%9.6%9.4%
ROE %0.0%10.2%9.6%0.0%10.7%9.3%7.6%
Debtor days1069897112107111109
Inventory days342162165199177250263
Days payable196127145160157198201
Cash conversion cycle253133117151126163171
Debt / equity2.491.961.772.062.021.941.94
Current ratio1.011.081.111.091.151.071.05
Net debt / EBITDA0.000.000.005.164.305.034.93

Compare with peers

Loading peers…